NeuroPace, Inc. 2021 Form 10-K Summary
Business Context and Reporting Period
NeuroPace is a commercial-stage medical device company focused on its RNS System, a brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The filing covers the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter financial statements.
- The RNS System is FDA-approved in the United States only for adults with drug-resistant focal epilepsy.
- Nearly 4,000 patients had received the system by December 31, 2021, and approximately 150 of roughly 200 U.S. Level 4 Comprehensive Epilepsy Centers performed initial implants during 2021.
- All 2021 revenue was generated in the United States.
Key Financial Metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $45.2 million | $41.1 million | +10% |
| Initial implant revenue | $33.7 million | $28.0 million | +20% |
| Replacement implant revenue | $11.5 million | $13.1 million | -12% |
| Gross profit | $33.4 million | $30.3 million | +10% |
| Gross margin | 74.0% | 73.6% | +0.4 percentage points |
| Research and development expense | $18.2 million | $15.7 million | +16% |
| SG&A expense | $39.0 million | $27.6 million | +41% |
| Loss from operations | $23.7 million | $13.1 million | Worsened by $10.7 million |
| Net loss | $36.1 million | $24.3 million | Worsened by $11.8 million |
| Net loss per share | $2.17 | $117.85 | Not comparable due to IPO and share-count changes |
| Cash used in operating activities | $24.6 million | $21.6 million | Increased by $3.0 million |
As of December 31, 2021, cash and cash equivalents were $19.2 million, short-term investments were $96.4 million, and total cash, cash equivalents and short-term investments were $115.6 million. Current liabilities were $9.3 million, and long-term debt was $49.8 million, net of discount and issuance costs. The company reported an accumulated deficit of $423.8 million and stockholders’ equity of $73.5 million.
Net cash used in investing activities was $85.4 million, primarily reflecting $85.0 million of purchases of short-term investments. Net cash provided by financing activities was $102.5 million, primarily from $109.1 million of net IPO proceeds, partially offset by $4.1 million of PPP loan repayment and $3.4 million of deferred offering costs.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by initial implants, while replacement revenue declined because the newer neurostimulator has an expected average battery life of nearly 11 years, compared with the previous eight-year assumption.
- Gross margin improved modestly because higher production volume reduced fixed manufacturing costs per unit.
- R&D expense increased as clinical study activity and personnel spending recovered from pandemic-related reductions in 2020.
- SG&A increased substantially due to higher headcount, incentive compensation, sales and marketing activity, and public-company costs.
- Interest expense declined to $7.4 million from $11.5 million, primarily because 2021 had lower average convertible-note and term-loan balances.
- Other expense was $5.4 million in 2021, primarily due to a $5.2 million increase in the fair value of the preferred-stock warrant liability before its conversion in connection with the IPO.
- The April 2021 IPO generated approximately $105.5 million of net proceeds. Preferred stock converted into common stock, and the company ended 2021 with approximately 24.5 million common shares outstanding.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide formal revenue or earnings guidance. Management expects continued net losses and negative operating cash flow for the next several years, while pursuing greater adoption, expanded sales capacity, product enhancements, and clinical studies supporting potential use in adolescents and patients with generalized epilepsy.
- Management believes available cash, cash equivalents and short-term investments will fund planned operations for at least 12 months from issuance of the financial statements, but expects longer-term capital may be required.
- The company’s $50 million term loan bears interest at 12.5%, is secured by substantially all assets including intellectual property, and requires a single principal payment in September 2025. The loan includes financial covenants, including minimum liquidity and annual revenue requirements.
- In March 2022, after year-end, the term loan was amended to reduce the minimum annual revenue covenant to $43.0 million for 2022. The company stated it was in compliance with its covenants as of December 31, 2021.
- COVID-19, Delta and Omicron materially reduced or delayed elective implants, epilepsy diagnostic evaluations and hospital access, particularly in the third and fourth quarters of 2021. Hospital staffing shortages and procedure backlogs may continue to affect results.
- The company relies on several single-source suppliers, including suppliers of critical printed circuit assemblies and batteries, and manufactures products at one Mountain View, California facility.
- Growth depends on market adoption, clinician training, reimbursement, regulatory approval for expanded indications, clinical outcomes, competition from VNS and DBS, and retention of specialized personnel.
- The company identified a material weakness in internal control over financial reporting involving segregation of duties for account reconciliations and manual journal entries. Remediation measures had been initiated but had not operated long enough to demonstrate remediation as of year-end. Management stated that the financial statements fairly present the company’s results.
- The company is responding to a U.S. Treasury inquiry concerning a matter that may fall under CFIUS jurisdiction. It is also defending shareholder litigation related to its reverse stock splits; no loss estimate was available.
- The company has no history of profitability, and the filing contains an inconsistency in narrative sections regarding the 2021 net loss. The audited financial statements and MD&A report a $36.1 million net loss; another business narrative cites $30.0 million.
Important Facts for Investors to Verify
- Reconcile the reported 2021 net loss across all filing sections and rely on the audited financial statements unless clarification is obtained.
- Monitor initial implant growth versus the expected decline in replacement procedures caused by longer battery life.
- Assess cash burn, liquidity, term-loan covenants and the timing of the September 2025 principal payment.
- Track the impact of COVID-19-related procedure backlogs, hospital staffing shortages and supply-chain constraints.
- Review progress and FDA requirements for adolescent and generalized-epilepsy indications; these uses were not yet approved for marketing.
- Evaluate remediation of the material weakness and the company’s transition to more extensive public-company internal-control requirements.
- Follow the CFIUS inquiry and reverse-stock-split litigation for potential financial, operational or reputational consequences.
- Confirm the sustainability of reimbursement, gross margins and market adoption against larger, better-capitalized competitors.